SUMMARY AMP-activated protein kinase (AMPK), a master regulator of cellular metabolism, is a potential target for type 2 diabetes. Although extensive in vitro studies have revealed the complex regulation of AMPK, much remains unknown about the regulation in vivo. We therefore developed transgenic mice expressing a highly sensitive fluorescence resonance energy transfer (FRET)-based biosensor for AMPK, called AMPKAR-EV. AMPKAR-EV allowed us to readily examine the role of LKB1, a canonical stimulator of AMPK, in drug-induced activation and inactivation of AMPK in vitro. In transgenic mice expressing AMPKAR-EV, the AMP analog AICAR activated AMPK in muscle. In contrast, the antidiabetic drug metformin activated AMPK in liver, highlighting the organ-specific action of AMPK stimulators. Moreover, we found that AMPK was activated primarily in fast-twitch muscle fibers after tetanic contraction and exercise. These observations suggest that the AMPKAR-EV mouse will pave a way to understanding the heterogeneous responses of AMPK among cell types in vivo.
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In Brief
Konagaya et al. report a highly sensitive FRET biosensor for AMP-activated protein kinase (AMPK). The biosensor readily discriminates cells with and without LKB1, a canonical AMPK activator and tumor suppressor. Transgenic mice expressing the AMPK-FRET biosensor highlight tissue-specific action of AMPK activators and fiber typespecific AMPK activation after exercise.
INTRODUCTION
The AMP-activated protein kinase (AMPK) regulates energy balance in the body (Mihaylova and Shaw, 2011; Carling et al., 2012; Hardie et al., 2012) . Intracellular deficiency in ATP activates AMPK, which, in turn, promotes catabolic processes and inhibits anabolic processes by phosphorylation of multiple substrates, including acetyl-coenzyme A (CoA) carboxylase (ACC) and hydroxymethylglutaryl-CoA (HMG-CoA) reductase. The linkage of AMPK to metabolic processes renders AMPK a promising therapeutic target for obesity and type 2 diabetes (Zhang et al., 2009 ).
AMPK is a heterotrimeric enzyme composed of a catalytic a subunit and two regulatory b and g subunits. The g subunit contains four cystathionine-b synthase (CBS) domains. Each CBS domain contains a binding site for an adenosine phosphate. Sites 1 and 3 bind AMP, ADP, or ATP in a concentration-dependent manner; site 4 constitutively binds to AMP; and site 2 is always empty. Phosphorylation of Thr 172 of the a subunit and allosteric activation, both due to binding of AMP to the g subunit, lead to a 1,000-fold increase in AMPK activity (Suter et al., 2006) . AMP binding to AMPK also inhibits dephosphorylation of AMPK (Davies et al., 1995) . Liver kinase B1 (LKB1) is the primary protein kinase responsible for the phosphorylation of this regulatory Thr 172 residue (Hawley et al., 2003; Woods et al., 2003; Shaw et al., 2004) . Increased intracellular AMP concentration drives assembly of the Axin-AMPK-LKB1 complex, thereby promoting AMPK phosphorylation by LKB1 . Thus, in addition to the multiple CBS domains, Axin-mediated regulation contributes to the ultrasensitive system for the monitoring of intracellular AMP concentration. Calcium/calmodulin-dependent protein kinase kinase 2 (CaMKK2, also known as CaMKKb) has also been shown to phosphorylate Thr 172 of the a subunit in a calcium-dependent manner (Hurley et al., 2005; Hawley et al., 2005) . This pathway is known to function at least in neurons and T cells (Mihaylova and Shaw, 2011; Carling et al., 2012; Hardie et al., 2012) .
Another class of AMPK regulator is peptidyl-prolyl cis/trans isomerase (PPIase) NIMA-interacting 1 (Pin1), which binds to a number of proteins and regulates oncogenesis and metabolic diseases (Khanal et al., 2013; Zhou and Lu, 2016) . Pin1 has been shown to bind to and inhibit AMPK; therefore, at least some effects of Pin1 on metabolism appear to be mediated by the Pin1-AMPK association.
The AMPK activity has been studied extensively by in vitro kinase assay and immunoblotting with anti-phospho-AMPK (pAMPK) or anti-phospho-ACC (pACC), which reflect mean AMPK activity in the cell population. To examine the heterogeneity of AMPK activity, Tsou et al. (2011) developed AMPKAR, a genetically encoded biosensor based on fluorescence resonance energy transfer (FRET) for AMPK activity, and revealed a very high cell-to-cell heterogeneity in the amplitude and time course using tissue culture cells. An improved version of AMPKAR has been developed and used to examine the AMPK activity in neurons (Sample et al., 2015) . A drawback of many FRET biosensors, including AMPKAR, may be low signal-to-noise ratio. We have reported that a long, flexible EV linker could significantly improve the dynamic range of many FRET biosensors by reducing the basal FRET signal (Komatsu et al., 2011) and that the resulting highly sensitive FRET biosensors enable us to visualize protein kinase activities in living mice, collectively called FRET mice (Kamioka et al., 2012) .
In this study, we have applied the EV linker technology to AMPKAR. The resulting AMPKAR-EV FRET biosensor exhibits three-fold higher dynamic range than AMPKAR and monitored AMPK activation in HeLa cells stimulated by 2-deoxyglucose (2-DG). Moreover, intravital imaging of transgenic mice expressing AMPKAR-EV has revealed that AMPK is predominantly activated in fast-twitch muscle fibers and that metformin activates AMPK in hepatocytes, but not in muscles. Thus, the in vivo imaging of AMPK activity will open a window to understanding the heterogeneous responses of AMPK among cell types in vivo.
RESULTS

AMPKAR-EV Monitors the Effect of Stimulators and an
Inhibitor on Endogenous AMPK Activity AMPKAR is a genetically encoded intramolecular FRET biosensor for monitoring AMPK activity in living cells (Tsou et al., 2011) . We developed AMPKAR-EV to increase the sensitivity by using a long, flexible EV linker (Komatsu et al., 2011) , and by replacing the yellow fluorescent protein (YFP) with YFP for energy transfer (YPet), a FRET-prone variant of YFP (Nguyen and Daugherty, 2005) . Phosphorylation of the substrate peptide by AMPK promotes its binding to the FHA1 domain and a conformational change of AMPKAR-EV, resulting in an increase in the FRET efficiency from super enhanced cyan fluorescent protein (SECFP) to YPet ( Figure 1A ). The fluorescence ratio of YPet to SECFP, hereinafter the FRET/CFP ratio, is used to represent the FRET efficiency. HeLa cells transiently expressing AMPKAR-EV were stimulated with 10 mM 2-DG, a glucose analog that perturbs glycolysis and reduces cytosolic ATP levels. We performed a side-by-side experiment with the prototype AMPKAR ( Figures 1B and 1C) . In contrast to the prototype AMPKAR, AMPKAR-EV exhibited a remarkably low FRET/CFP ratio, primarily because the EV linker decreases the association of SECFP and YPet in the absence of phosphorylation of the substrate (Komatsu et al., 2011) . After 2-DG stimulation, AMP-KAR-EV, but not the prototype AMPKAR, showed a robust and rapid change in the FRET/CFP ratio. The low response of the prototype AMPKAR to 2-DG in HeLa cells agrees with the previous report (Tsou et al., 2011) . To examine the correlation of the FRET/CFP ratio with AMPK activity, immunoblotting experiments and FRET imaging were performed side by side in HeLa cells stably expressing AMPKAR-EV. The temporal dynamics of pACC levels were similar to those of AMPKAR-EV ( Figure 1C ). Moreover, 2-DG-induced phosphorylation of ACC was correlated almost linearly with the FRET/CFP ratio (correlation coefficients = 0.92 and 0.95) ( Figure 1D ). We also tested whether the increase in the FRET/CFP ratio required endogenous AMPK by using AMPK-double knockout (DKO) HEK293A cells, which lack both AMPKa1 and AMPKa2 (PRKAA1 and PRKAA2) genes. The basal FRET/CFP ratio was markedly higher in the wild-type (WT) HEK293A cells than in the AMPK-DKO HEK293A cells (Figure 1E) . Moreover, 2-DG increased the FRET/CFP ratio only in WT HEK293A cells. Thus, AMPKAR-EV is specific to AMPK and sensitive enough to detect 2-DG-stimulated AMPK activation.
We further examined the response of AMPKAR-EV for two AMPK stimulators that have different modes of action. A-769662 is a thienopyridone and directly activates AMPK by inducing interaction between the b and the g subunits of AMPK (Gö ransson et al., 2007; Xiao et al., 2013) . On the other hand, 5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside (AICAR) is phosphorylated to yield an AMP analog, 5-aminoimidazole-4-carboxamide-1-b-D-ribofuranotide (ZMP), which binds to AMPK and thereby promotes net phosphorylation by LKB1 (Corton et al., 1995; Zhang et al., 2013) . A-769662 induced a rapid increase in the FRET/CFP ratio in AMPKAR-EV-expressing Colon 38 cells ( Figure 1F ). The temporal dynamics of the FRET/CFP ratio were comparable to those of pACC. Dose responses revealed that the 50% effective concentration (EC 50 ) of A-769662 was $50 mM under our experimental conditions ( Figure 1G ). Similarly, the EC 50 of AICAR was determined as $0.5 mM in Colon 38 cells. These values are similar to those reported previously (Cool et al., 2006; Gö ransson et al., 2007) . Altogether, these results support the notion that AMPKAR-EV faithfully represents AMPK activity in tissue culture cells.
AMPKAR-EV Delineates Roles of LKB1 in the Basal
Activity and Drug-Induced Activation of AMPK Activity LKB1, a major regulator of AMPK (Hawley et al., 2003; Woods et al., 2003; Shaw et al., 2004) , is often suppressed in cancer cells. We therefore examined whether the basal AMPK activity detected by AMPKAR-EV correlated with the expression of LKB1. We used HepG2, Colon 38, and 3LL cells as cell lines retaining intact LKB1 and used A549, H460, and HeLa cells as cell lines deficient for LKB1. As expected, ACC was more phosphorylated in LKB1-intact cells than that in LKB1-deficient cells, although the level of phosphorylation differed significantly among the LKB1-intact cells ( Figure S1 ). In agreement with this observation, the FRET/CFP ratio clearly grouped the cell lines into LKB1-positive and LKB1-negative cell lines (Figure 2A) . Consistently, HeLa cells exhibited high basal AMPK activity by the expression of WT, but not by that of kinase-deficient LKB1.
We further examined the cellular response to AICAR, metformin, 2-DG, and A-769662, which have been shown to activate AMPK in an LKB1-dependent or LKB1-independent manner. Metformin is one of the most widely used anti-diabetic drugs; it acts by inhibiting respiratory-chain complex I and thereby increasing the AMP/ATP ratio (Viollet et al., 2012) . As reported previously (Shaw et al., 2004; Shackelford et al., 2013) , AICAR and metformin increased the FRET/CFP ratio in the LKB1-expressing cell lines Colon 38, HepG2, and 3LL, but not in the LKB1-deficient cell lines A549, H460, and HeLa ( Figure 2B ). In contrast to AICAR and metformin, 2-DG induced a rapid and sustained increase in the FRET/CFP ratio irrespective of the expression of LKB1. We found that A-769662 elicited two phases of AMPK activation: a rapid and transient increase 10 to 20 min after the stimulation and a gradual second-phase increase after 30 min. The mechanism of this two-phase increase is unknown.
Because the increase in the FRET/CFP ratio by 2-DG was also observed in LKB1-deficient cells, we examined the contribution of the Ca 2+ -CaMKK2 pathway to 2-DG-induced AMPK activation. As expected, the intracellular Ca 2+ chelator BAPTA-AM, the CaMKK2 inhibitor STO-609, and a small interfering RNA (siRNA) against CaMKK2 ablated the 2-DG-induced increase in the FRET/CFP ratio ( Figure S2A ). The consistent effect of the CaMKK2 was confirmed by immunoblotting with anti-pACC antibody ( Figure S2B ). Similar results were obtained using A549 ( Figures S2C and S2D ). By using R-GECO1.0, which is a Ca 2+ indicator, we confirmed that intracellular Ca 2+ levels were increased upon 2-DG stimulation, irrespective of AMPKAR-EV expression ( Figure S2E ). All of these results are consistent with the idea that the 2-DG-induced AMPK activation in LKB1-deficient cell lines depends on the Ca 2+ -CaMKK2 pathway and that AMPKAR-EV faithfully reports the AMPK activity in the presence of various stimulators and inhibitors.
Pin1 Inhibits LKB1-Dependent, but not CaMKK2-Dependent, AMPK Activation Pin1, a PPIase, has been shown to suppress AMPK by direct binding to phospho-Ser 176 of AMPK (Khanal et al., 2013) and phospho-Thr 211 of AMPK (Nakatsu et al., 2015) . However, it has not been determined whether Pin1 inhibits both LKB1-and CaMKK2-dependent AMPK activation. To answer this question, we examined the effect of Pin1 on AMPK activity in the presence or absence of LKB1. We found that the basal FRET/CFP ratios were decreased by Pin1 overexpression in LKB1-expressing cells, including HepG2 cells, Colon 38 cells, and LKB1-expressing HeLa cells, but not in the authentic LKB1-deficient HeLa cells ( Figure 3A ). By contrast, Pin1 inhibitors increased the FRET/ CFP ratio only in the LKB1-expressing HeLa cells, not in the authentic HeLa cells ( Figure 3B ). Collectively, these results indicate that Pin1 inhibits LKB1-dependent AMPK activation under unstimulated conditions. Next, therefore, we examined the effect of Pin1 under stimulated conditions. The authentic and LKB1-expressing HeLa cells were infected with Pin1-expressing lentivirus and time-lapse imaged to examine the effect of AMPK stimulators ( Figures 3C and 3D ). In the authentic HeLa cells, AICAR failed to exhibit any effects irrespective of the expression of Pin1. In the LKB1-expressing HeLa cells, Pin1 not only decreased the basal FRET/CFP ratio but also abrogated AICAR-induced increase in the FRET/CFP ratio. In contrast to AICAR, 2-DG markedly increased the FRET/CFP ratio, irrespective of the presence of LKB1 or Pin1 ( Figure 3D ). Because we have shown that 2-DG activates AMPK via the Ca 2+ -CaMKK2 pathway ( Figure S2 ), these results demonstrated that Pin1 inhibits LKB1-dependent, but not CaMKK2-dependent, AMPK activation.
Myocytes and Hepatocytes Respond to AICAR and Metformin Differently
Encouraged by the in vitro data showing that AMPKAR-EV could monitor AMPK activity under various conditions, we generated Figure S1 . LKB1 or kinase-dead LKB1 was expressed in HeLa cells (HeLa + LKB1WT and HeLa + LKB1KD, respectively). (B) Cells expressing AMPKAR-EV were stimulated with the following agents: 10 mM 2-DG, 50 mM A-769662, 1 mM AICAR, and 10 mM metformin. The averaged FRET/CFP ratios are shown (bars, SDs; n = more than 16 cells across more than 3 fields of view). Gray dashed lines denote the initial values. Statistical significance of the averaged FRET/CFP was assessed between the initial time point and 54 min after the stimulation (***p < 0.001; *p < 0.05; n.s., not significant). See also Figures S1 and S2.
Time ( transgenic mice expressing AMPKAR-EV by Tol2-mediated gene transfer (Kamioka et al., 2012) . The transgenes were transmitted to offspring by Mendelian inheritance across five generations (continued transmission in this line is ongoing). Animals transgenic for FRET biosensors grew normally and showed no external or internal signs of malformations or other adverse reactions to the transgene. The CAG promoter-driven expression of AMPKAR-EV was sufficiently robust to identify newborn transgenic mice by visual inspection of green fluorescence in the skin. Expression of AMPKAR-EV was confirmed in most, if not all, organs examined by visual inspection and in vivo imaging by two-photon excitation microscopy. One of the prospective applications of FRET mice is for the study of pharmacodynamics. Here, we attempted to visualize the effect of AICAR and metformin in the liver and the skeletal muscle (Figure 4) . In muscle cells, AICAR, but not metformin, induced a transient increase in the FRET/CFP ratio (Figures 4B and 4C; Movie S1). In contrast, the FRET/CFP ratio in hepatocytes was gradually increased only by metformin ( Figures 4E  and 4F ). Immunoblotting analysis confirmed the organ-specific effect of AICAR and metformin on pAMPK levels. Thus, these data demonstrate that the AMPKAR-EV mouse is a powerful tool for comparing the pharmacodynamics of stimulators and inhibitors of AMPK among different tissues. We also examined whether we could detect AMPK activation upon starvation. For this, mice were starved for one or two days, and AMPK activity was monitored in the liver ( Figure 4G ). Hepatocytes in starved mice showed higher FRET efficiency than those in fed mice, representing that the AMPKAR-EV mouse reports the AMPK activation under a physiological stimulus. We also confirmed the effect of starvation in each mouse by measuring blood glucose levels and AMPK phosphorylation ( Figure 4G ).
AMPKAR-EV Mice Reveal AMPK Activation in FastTwitch Fibers after Contraction In Vivo
Another promising application of the transgenic mice expressing AMPKAR-EV is for the examination of heterogeneous responses of cell types within a tissue of interest. In skeletal muscles, fibers are largely classified into white fast-twitch muscles, characterized by glycolytic metabolism, and red slow-twitch muscles, characterized by oxidative metabolism. We examined whether any muscle fiber type-specific difference could be observed in the AMPK activity by observing the biceps femoris after tetanic contraction or exercise. After stimulation, mice were subjected to in vivo imaging. To increase the number of muscle fibers to be analyzed, one to four fields of view were imaged in each mouse. The image acquisition started approximately 5 min and no later than 31 min after the stimulation; in no case were images captured later than 40 min after the stimulation. Precise intervals between the stimulation and the imaging are described in Figure S3 . ) and total AMPK following addition of AICAR or metformin were also analyzed by immunoblotting. (G) Normalized FRET/CFP is plotted against blood glucose levels. AMPKAR-EV mice were fasted for more than 24 or 48 hr. AMPKAR-EV mice fed ad libitum were used as a control. Glucose (1 g/kg) was injected intravenously at 0 min. The averaged FRET/CFP ratios just before the glucose addition were normalized by the values 60 min after the stimulation (n = 4 independent experiments with more than 15 hepatocytes). pAMPK (Thr 172 ) and total AMPK after starvation were also analyzed by immunoblotting. Refer to Movie S1. Figure S3 for the detailed interval between the stimulation and the in vivo imaging. White arrowheads indicate NAD(P)H-high fibers.
(D) The FRET/CFP ratio is plotted against normalized NAD(P)H intensity. To minimize the depth effect, NAD(P)H intensity was normalized by dividing the average of the entire image. 10 to 50 fibers in each mouse were imaged, quantified, and presented in the figure. Each shape (triangles, circles, or diamonds) represents the In the control mice, the FRET/CFP ratio in each muscle fiber differed to some extent; however, the heterogeneity was significantly increased after electrically induced tetanic contraction ( Figure 5A ). Fluorescence of 430 nm can be used to quantify NAD(P)H and thereby identify the muscle fiber types, because NAD(P)H is abundant in mitochondria-rich, red slow-twitch muscle fibers (Piston et al., 1995; Rothstein et al., 2005) . We found that NAD(P)H-high fibers were smaller in diameter and lower in FRET/CFP ratio than NAD(P)H-low fibers ( Figure 5A ). The proportion and diameter of NAD(P)H-high fibers were similar to those of fibers heavily stained by NADH-TR, supporting the muscle fiber typing by NAD(P)H fluorescence ( Figure 5B ). We extended this approach to examine the specificity of our findings by using transgenic mice expressing FRET biosensors for ERK and PKA and a negative control FRET biosensor, PKA-NC (Figure 5C) . Quantification of the FRET/CFP ratio and NAD(P)H intensity demonstrated clearly that AMPK was activated preferentially in NAD(P)H-low fibers 0 to 40 min after electronically induced tetanic contraction ( Figure 5D ). Similar results were obtained for ERK. Upon muscle contraction, the FRET/CFP ratio in transgenic mice expressing the FRET biosensor for ERK was significantly increased in NAD(P)H-high muscle fibers. The increase in the FRET/CFP ratio was mostly confined to the muscle fibers beneath the muscular fascia, suggesting that the ERK activity was regulated not by the type of muscle fibers but rather by the location within the muscle. In contrast, the transgenic mice expressing the FRET biosensor for PKA or the negative control FRET biosensor did not show a significant increase in the FRET/CFP ratio in the muscle. Collectively, these data suggest that AMPK is activated in fast-twitch fibers after tetanic contraction.
Finally, we investigated whether treadmill exercise is able to activate AMPK in fast-twitch fibers specifically. Mice were trained according to a previous report (Maarbjerg et al., 2009) and then forced to run on a treadmill for 60 min at 16 m/min. After treadmill running, there were some myofibers with high AMPK activity, especially in NAD(P)H-low fibers ( Figure 5E ). This result supports our model that AMPK is activated in fast-twitch fibers. In conclusion, the transgenic mouse expressing AMPKAR-EV is a powerful tool to detect the minor population and examine the heterogeneous responses of AMPK in vivo.
DISCUSSION
By the use of a flexible EV linker, the basal level of the FRET/CFP ratio was markedly decreased in comparison to that for the prototype, AMPKAR (Figures 1B and 1C) . This decreased basal signal of AMPKAR-EV allowed us to classify cells easily into two groups based on the expression of LKB1 (Figure 2 ). In agreement with previous reports (Hawley et al., 2003; Woods et al., 2003; Shaw et al., 2004; Gowans et al., 2013) , this significant difference in the basal AMPK activity indicates that LKB1 phosphorylates and activates AMPK even in nutrient-rich culture medium. It should be recalled that AMPK-dependent phosphorylation inactivates ACC and HMG-CoA reductase. Thus, the basal activities of LKB1 and AMPK may play a role in reserving inert ACC and HMG-CoA reductase. In this context, we may need to pay more attention to signals that reduce LKB1 activity under nutrient-rich conditions. Pin1 has been shown to bind to and inactivate AMPK (Khanal et al., 2013; Nakatsu et al., 2015) . The binding of Pin1 to the CBS3 domain of the AMPK g subunit exposes phospho-Thr 172 of the a subunit for the dephosphorylation by PP2C and thereby suppresses AMPK activity (Nakatsu et al., 2015) . By using cell lines expressing AMPKAR-EV, we found that Pin1 inhibits AMPK activation by LKB1, but not by CaMKK2 (Figures 3 and  S2) , suggesting an LKB1-specific mechanism of inhibition. LKB1 phosphorylates AMPK on a scaffold protein, Axin . It remains unknown which subunit of AMPK binds to Axin; however, we could speculate that Pin1 binding to AMPK inhibits the association of AMPK with Axin and thereby prevents AMPK from LKB1-dependent phosphorylation. This scenario can also explain why Pin1 did not inhibit CaMKK2-dependent AMPK activation.
The difference in the AMPK activity between slow-and fasttwitch fibers has been controversial. Narkar et al. (2011) found that AMPK was more active in the soleus (predominantly slowtwitch myofibers) than the quadriceps (predominantly fasttwitch myofibers). Meanwhile, other research groups failed to find significant difference in AMPK activity between the soleus and the extensor digitorum longus (predominantly fast-twitch myofibers) (Dzamko et al., 2008; Jensen et al., 2007; Jørgensen et al., 2004) . These studies were based mostly on immunoblotting with anti-pAMPK; therefore, they do not necessarily show the difference between fast-and slow-twitch fibers. The use of AMPKAR-EV enabled us to examine the AMPK activity directly in each fiber type before and after stimulation ( Figure 5 ). Our data strongly suggested that only the fast-twitch myofibers exhibited an increase in AMPK activity upon tetanic contraction and exercise. We may speculate that the tetanic contraction and the exercise causes ATP consumption primarily in fast-twitch myofibers, resulting in strong AMPK activation. Although we cannot rule out the possibility that AMPK activation in the slow-twitch myofibers was transient, and therefore could not be detected in our experimental protocol, it is unlikely that such transient AMPK activation alters the metabolic states of the slow-twitch myofibers. It would be interesting to test whether low-intensity, long-time exercise may activate AMPK preferentially in the slow-twitch myofibers.
dataset from the same mouse before and after stimulation. Histograms of the normalized NAD(P)H intensity and FRET/CFP ratio are shown at the top and right side of the figure, respectively. For statistical analysis, the datasets were divided into two groups by the threshold of normalized NAD(P)H = 2. Statistical significance of the averaged FRET/CFP was assessed by t test between before and after stimulation in categorized fibers (**p < 0.01; *p < 0.05; n.s., not significant; p values are given in parentheses). (E) Similar experiments were performed as in (D). Trained mice expressing AMPKAR-EV were run on a treadmill for 60 min at 16 m/min. Image acquisition was started 6 to 25 min after the end of running and finished in 40 min. AMPKAR-EV mice without training were used as a control (*p < 0.05; n.s., not significant; p values are given in parentheses).
Because of the critical roles played by AMPK in energy sensing and cancer cell survival, a huge number of drugs have been proposed to exert their pharmacological effects by means of AMPK activation (Kim and He, 2013) . For example, metformin has been shown to activate AMPK in muscle (Sajan et al., 2010; Kristensen et al., 2014) , liver (Shaw et al., 2005; Sajan et al., 2010; Tajima et al., 2013) , brain (Chen et al., 2009; Duan et al., 2013; Cho et al., 2015) , and pancreatic cancer cells (Hinke et al., 2007; Kisfalvi et al., 2009; Sinnett-Smith et al., 2013) ; however, the difficulty of performing direct comparisons among experimental setups renders the effect of metformin obscure, even if we admit the pleiotropic effects of this agent. Intravital imaging of AMPK activity by using AMPKAR-EV-expressing transgenic mice has enabled us to visualize the influence of AMPK-activating reagents to different organs on the same scale. We found that effect of metformin on AMPK activity differs substantially between liver and skeletal muscle (Figure 4) . The reason for this tissue-specific action of metformin is probably because a metformin transporter, organic cation transporter 1 (OCT1), is expressed preferentially in the liver (Wang et al., 2002) . Similarly, the expression level of OCT1 in each cell line could affect the responsiveness to metformin in vitro. In the six cell lines analyzed in this study, the expression of LKB1 was perfectly correlated with the reactivity to metformin; however, this observation does not rule out that low OCT1 expression abolishes the reactivity to metformin in vitro.
AICAR-induced AMPK activation was observed in previous studies using isolated hepatocytes from mice (Foretz et al., 2010) and rats (Corton et al., 1995) and, in the present study, using hepatic cancer-derived HepG2 cells ( Figure 2B ). However, only a few reports described similar results in vivo. After two weeks of administration of AICAR, AMPK activity in the liver is increased approximately two-fold in mice (Liu et al., 2015) . To our knowledge, only two studies reported in vivo AMPK activation after acute administration of AICAR (Buhl et al., 2002; Sajan et al., 2010) . By using obese Zucker (fa/fa) rats and SpragueDawley rats, the authors reported a two-to three-fold increase of AMPK activity and pAMPK (Thr 172 ) by AICAR and a threefold increase by metformin, indicating that metformin more potently activates AMPK in the liver than does AICAR. We also found AMPK activation by metformin in the liver but failed to detect the effect of AICAR (Figure 4 ). The discrepancy may be ascribable to the difference between mice and rats. Because AICAR must be transported into the liver and phosphorylated to yield ZMP for its action, the kinetics of AMPK activation by AICAR may be influenced by the transporters and kinases, of which activity may vary among species and organs. Although the mechanism of muscle-specific action of AICAR in mice is elusive, these findings give us a clue to understanding the effectiveness of metformin for type 2 diabetes mellitus and AICAR for sports doping, respectively (Hardie et al., 2012) . Because many pro-AMPK reagents exert their effect through decreasing intracellular ATP concentration, use of transgenic mice expressing FRET biosensors for ATP (Imamura et al., 2009 ) will also be informative in understanding the regulation of AMPK in vivo. In summary, we generated a highly sensitive AMPK biosensor, AMPKAR-EV, and established a protocol to visualize AMPK activity in living mice. These transgenic mice expressing AMPKAR-EV will be a powerful tool for understanding AMPK activity in individual cell types and organs. Because the importance of the AMPK pathway has been identified in autophagy, aging, immunity, and inflammation, in addition to cancer and metabolism, AMPKAR-EV mice are expected to provide valuable information about AMPK activity in various fields.
EXPERIMENTAL PROCEDURES
For detailed methods, see also Supplemental Experimental Procedures.
AMPKAR-EV Mice
The animal protocols were reviewed and approved by the Animal Care and Use Committee of Kyoto University Graduate School of Medicine (No. 14079, 15064, 16038, and 17539) . To develop transgenic mice expressing AMPKAR-EV, Lox-Stop-Lox (LSL)-tdKeima-AMPKAR-EV mice were generated by cytoplasmic microinjection into fertilized eggs of B6C3F1 mice with Tol2 mRNA and pT2A-derived LSL-tdKeima-AMPKAR-EV vector as described previously (Sumiyama et al., 2010) . Transgenic male mice were crossed with B6.FVB-Tg (EIIa-cre) C5379Lmgd/J female mice (a gift from Mitinori Saitou, Kyoto University, Kyoto, Japan) for the ubiquitous expression of AMPKAR-EV. Mice were backcrossed with C57BL/6 for at least two generations before analyses.
Mice were housed in a specific pathogen-free facility and received a routine chow diet and water ad libitum. To date, no disease or anomaly has been associated with the transgenic mice used in this study. 4-to 40-week-old male and female mice were used for the in vivo imaging.
Plasmids
The AMPKAR-EV was generated by substitution of the kinase substrate peptide in the previously described Eevee backbone (Komatsu et al., 2011) . From the N terminus, AMPKAR-EV consists of YPet, a spacer (Leu-Glu), the FHA1 domain of yeast Rad53 (aa 241-382), a spacer (Gly-Thr), the EV linker, a spacer (Ser-Gly), the substrate peptide (GSGEGSTKMRRVATLVDLGTGG SEL), a spacer (Gly-Gly-Arg), SECFP, a spacer (Ser-Arg), and the nuclear export signal peptide of the HIV-1 Rev protein (LQLPPLERLTLD). The cDNA of AMPKAR-EV was inserted into pPBbsr, consisting of a piggyBac transposon vector (Yusa et al., 2009) . pCMV-mPBase (mammalian codon-optimized PBase) encoding a piggyBac transposase was a gift from Allan Bradley (Welcome Trust Sanger Institute, Cambridge, UK).
Observation of the Skeletal Muscle and the Liver Living mice were observed with an FV1000MVE inverted microscope (Olympus, Tokyo, Japan) equipped with a UplanSApo 303/1.05 silicon oil-immersion objective lens (Olympus) or an FV1200MPE-BX61WI upright microscope (Olympus) equipped with a UplanSApo 253/1.05 numerical aperture (NA) water-immersion objective lens (Olympus). The microscopes were equipped with an InSight DeepSee Ultrafast laser (0.95 W at 900 nm) (Spectra Physics, Mountain View, CA). The scan speed was set for 2 to 12.5 ms/pixel. The excitation wavelength for CFP was 840 nm, and that for NAD(P)H was 780 nm. Fluorescent images were acquired with the following filters and mirrors: an infrared (IR)-cut filter, BA685RIF-3; two dichroic mirrors, DM505 and DM570; and three emission filters, FF01-425/30 (Semrock, Rochester, NY) for second harmonic generation (SHG) and NAD(P)H, BA460-500 (Olympus) for CFP, and BA520-560 (Olympus) for FRET. The microscopes were equipped with a two-channel GaAsP detector unit and two multialkali detectors. FluoView software (Olympus) was used to control the microscope and to acquire images, which were saved in the multilayer 12-bit tagged image file format. Acquired images were processed and analyzed with Metamorph software as described previously (Kamioka et al., 2012) . Intravital mouse imaging was performed essentially as described previously (Kamioka et al., 2012) . For observation of the skeletal muscle, the mouse was placed in the prone position on an electric heat pad maintained at 37 C. The skin over the thigh was flapped to expose approximately 1 cm 2 of the biceps femoris, which was set over the objective. For observation of the liver, the abdominal wall was incised to expose approximately 0.25 cm 2 of the tissue. The exposed tissue was imaged using an aspiration fixation system (Sano et al., 2016) . Drugs were injected intravenously during imaging.
Energy Stress Manipulation
For electrically induced muscle contraction, the femoral nerve was stimulated with a NEPA21 electroporator (Nepa Gene, Chiba, Japan) at a voltage of 40 V. A tetanic contraction was obtained using 180 pulses at 5 Hz (O'Neill et al., 2011; Pratt and Lovering, 2014) . Immediately after the stimulation, mice were anesthetized and subjected to in vivo imaging, which started approximately 5 min and no later than 31 min after the end of stimulation; in no case were images captured later than 40 min after the stimulation. For the detection of exercise-induced AMPK activation, according to a previous report (Maarbjerg et al., 2009 ), mice were acclimatized to treadmill running before the experiment from day À5 to day À2 using an MK-680 treadmill (Muromachi-Koki, Tokyo, Japan). Initially, mice were allowed to rest in the treadmill apparatus for 10 min and then exercised by running for 5 min at 10 m/min and 5 min at 16 m/min at 0% incline. Before imaging, mice ran for 60 min at 16 m/min on a 0% incline. If necessary, electrical shock was applied to encourage running during both the acclimatization and the experiment. Immediately after the exercising, mice were anesthetized and subjected to in vivo imaging, which started 6 to 25 min after the end of exercising; in no case were images captured later than 40 min after the exercising ( Figure S3 ).
For fasting, mice were single-caged and maintained in standard cages without accesses to food for more than 24 or 48 hr. To confirm fasting status, blood glucose levels were measured using a blood glucose monitor (Glutest Neo Sensor; Sanwa Kagaku Kenkyusho, Nagoya, Japan). Histochemical analysis of NADH tetrazolium reductase (NADH-TR) was performed as previously described (Hoshino et al., 2013) .
Quantification and Statistical Analysis
The statistical differences between the two experimental groups were assessed by Student's two-sample t test. 
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